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Abstract
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of pathologically activated
immature myeloid cells that expand and accumulate in cancer, and are categorized as M-MDSC or PMN-
MDSC. The role of MDSC to suppress T-cell activation and proliferation in the tumor microenvironment has
been clarified over the past 15 years. Our lab has previously demonstrated that an inflammatory environment
can lead to the expansion of “MDSC-like” cells that lack immunosuppressive capability. However, the role of
these MDSC-like cells in cancer has not been elucidated. First, we hypothesized that PMN-MDSC-like cells
will develop in relatively low inflammatory conditions, such as the early stages of tumor development. Next,
we hypothesized that because bona fide PMN-MDSC must migrate into tissues to exert their
immunosuppressive effects, PMN-MDSC-like cells that lack immunosuppressive capability will exhibit
altered migratory behavior. Finally, because many immune cells undergo metabolic reprogramming to meet
the energetic demands of their functionality, we hypothesized that PMN-MDSC-like cells would alter their
metabolic profile compared to na�ve PMN and bona fide PMN-MDSC. We have demonstrated that PMN-
MDSC-like cells develop in the early stages of tumor development and in transgenic models, but not in the
late stages of tumor development or in transplantable models. Moreover, we have found that PMN-MDSC-
like cells spontaneously migrate 2-3 fold more than na�ve PMN, and that this motility is characterized by
increased speed, persistence time, mean squared displacement and an overall increased random motility
coefficient. We demonstrated that PMN-MDSC-like cell spontaneous migration is dependent upon
pannexin-1 hemichannel-mediated ATP release, autocrine ATP signaling through the P2X1 purinergic
receptor, and increased pMLC2 levels. Additionally, we have shown that PMN-MDSC-like cells increase cell
surface expression of the glucose transporter Glut1. Finally, we have shown that, in comparison to na�ve
PMN and bona fide PMN-MDSC, PMN-MDSC-like cells increase their glycolytic rate to meet the energetic
demands of their altered migratory behavior. Collectively, these studies have shed insight on the development
of bona fide PMN-MDSC in cancer, and have suggested a role for PMN-MDSC-like cells in pre-metastatic
niche development.
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ABSTRACT 
 
A UNIQUE PATTERN OF PMN-MDSC MIGRATION IN CANCER 
Sima N. Patel 
Dmitry I. Gabrilovich, MD, PhD 
 
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of 
pathologically activated immature myeloid cells that expand and accumulate in cancer, and 
are categorized as M-MDSC or PMN-MDSC. The role of MDSC to suppress T-cell 
activation and proliferation in the tumor microenvironment has been clarified over the past 
15 years. Our lab has previously demonstrated that an inflammatory environment can lead 
to the expansion of “MDSC-like” cells that lack immunosuppressive capability. However, 
the role of these MDSC-like cells in cancer has not been elucidated. First, we hypothesized 
that PMN-MDSC-like cells will develop in relatively low inflammatory conditions, such 
as the early stages of tumor development. Next, we hypothesized that because bona fide 
PMN-MDSC must migrate into tissues to exert their immunosuppressive effects, PMN-
MDSC-like cells that lack immunosuppressive capability will exhibit altered migratory 
behavior. Finally, because many immune cells undergo metabolic reprogramming to meet 
the energetic demands of their functionality, we hypothesized that PMN-MDSC-like cells 
would alter their metabolic profile compared to naïve PMN and bona fide PMN-MDSC. 
We have demonstrated that PMN-MDSC-like cells develop in the early stages of tumor 
development and in transgenic models, but not in the late stages of tumor development or 
in transplantable models. Moreover, we have found that PMN-MDSC-like cells 
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spontaneously migrate 2-3 fold more than naïve PMN, and that this motility is 
characterized by increased speed, persistence time, mean squared displacement and an 
overall increased random motility coefficient. We demonstrated that PMN-MDSC-like cell 
spontaneous migration is dependent upon pannexin-1 hemichannel-mediated ATP release, 
autocrine ATP signaling through the P2X1 purinergic receptor, and increased pMLC2 
levels. Additionally, we have shown that PMN-MDSC-like cells increase cell surface 
expression of the glucose transporter Glut1. Finally, we have shown that, in comparison to 
naïve PMN and bona fide PMN-MDSC, PMN-MDSC-like cells increase their glycolytic 
rate to meet the energetic demands of their altered migratory behavior. Collectively, these 
studies have shed insight on the development of bona fide PMN-MDSC in cancer, and have 
suggested a role for PMN-MDSC-like cells in pre-metastatic niche development. 
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CHAPTER ONE: MYELOID-DERIVED SUPPRESSOR CELLS 
 
Introduction 
Cancer is the second leading cause of death in the United States and affects patients 
and families worldwide. In 2017 alone, it is estimated that approximately 600,000 
Americans will die from cancer (Siegel, Miller, & Jemal, 2017). While conventional 
therapies, such as surgery, chemotherapy, and radiation therapy have proved successful at 
treating specific cancers, we are still struggling to achieve long-term success in patients, 
often because of disease recurrence. In fact, metastases are the cause of 90% of human 
cancer deaths (Mehlen & Puisieux, 2006). To address this impasse, on December 13, 2016, 
President Obama signed the 21st Century Cures Act, ensuring funding for initiatives from 
the Beau Biden Cancer Moonshot, which includes the development of immunotherapies 
(AACR, 2017). Immunotherapies are an attractive therapeutic approach as they activate 
the patient’s own immune system to selectively target tumor cells. However, tumors have 
developed mechanisms to evade immune surveillance and the immunosuppressive tumor 
microenvironment presents a significant challenge to the efficacy of immunotherapies 
(Mellman, Coukos, & Dranoff, 2011).  
Immune suppressive myeloid cells were observed in tumor-bearing hosts beginning 
in the early 1970s, and in 2007, these cells were termed myeloid-derived suppressor cells 
(MDSC) to reflect their origin and function (T. Condamine, Ramachandran, Youn, & 
Gabrilovich, 2015; D. I. Gabrilovich et al., 2007). MDSC accumulation has been reported 
in many cancers and studies have shown a correlation between levels of MDSC 
accumulation and stage, overall survival, and response to therapy. Several studies have also 
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found a correlation between MDSC and the development of metastases in patients (T. 
Condamine et al., 2015). Moreover, analysis of blood samples from patients that did not 
respond to immunotherapy indicated a correlation between MDSC level and lack of 
response (Kimura et al., 2013). Given the importance of these cells in cancer progression 
and their significance in the efficacy of immunotherapies, it is essential that we learn more 
about their biology and mechanism of action if we are to design therapies to effectively 
treat patients. 
MDSC phenotype 
 
MDSC are a heterogeneous population of pathologically activated immature 
myeloid cells that are phenotypically similar to myeloid cells in healthy individuals. These 
cells were described as CD11b+GR1+ cells in mice, and were found to accumulate in the 
spleen and bone-marrow of tumor-bearing mice (D. I. Gabrilovich, Velders, Sotomayor, & 
Kast, 2001; Kusmartsev, Li, & Chen, 2000). Based on their morphology and surface 
molecule expression, MDSC are divided into two subpopulations: mononuclear MDSC 
(M-MDSC) and polymorphonuclear MDSC (PMN-MDSC). M-MDSC, similar to 
monocytes, have a single-lobed nucleus and are defined in mice as CD11b+Ly6ChiLy6G-, 
and PMN-MDSC, similar to PMN, have a multi-lobed nucleus and are defined in mice as 
CD11b+Ly6CloLy6G+ (Figure 1.1). With the isolation strategies currently available to us, 
it is impossible to differentiate between PMN and PMN-MDSC in mice. Therefore, it is an 
accepted convention in the field to assume that all CD11b+GR1+ cells from a mouse are 
MDSC. In human patients, however, we are able to distinguish between PMN and PMN-
MDSC using density centrifugation. The high-density fraction of cells contain PMN, and 
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the low-density cells contain MDSC, though there is some controversy in the field, as it is 
believed that some activated PMN can also be present in the low density fraction (Moses 
& Brandau, 2016). From the low density fraction, PMN-MDSC are defined as 
CD11b+CD14-CD15+ or CD11b+CD14-CD66b+, and M-MDSC as CD11b+CD14+HLA-
DR-/loCD15- (D. I. Gabrilovich, 2017).  
MDSC and inflammation 
 
Inflammation contributes to the development of cancer, and chronic inflammation 
can drive MDSC accumulation and suppressive function (Balkwill & Mantovani, 2001; K. 
H. Parker, Beury, & Ostrand-Rosenberg, 2015). Tumor-secreted factors such as VEGF, 
MMP9, GM-CSF, COX2, PGE2, and HMGB1 have been implicated in the accumulation 
and function of MDSC (D. Gabrilovich et al., 1998; Melani, Sangaletti, Barazzetta, Werb, 
& Colombo, 2007; Morales, Kmieciak, Knutson, Bear, & Manjili, 2010; K. Parker et al., 
2014; Serafini et al., 2004). In mice, there is some evidence to suggest that inflammation 
may lead to the accumulation of MDSC-like cells. For example, exposure to cigarette 
Figure 1.1 Phenotype of murine MDSC. CD11b+ cells were gated from the live cell 
population (AQUA-negative). From the Cd11b+ cells, M-MDSC are identified as 
Ly6ChiLy6G-, and PMN-MDSC are identified as Ly6CloLy6G+. 
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smoke causes the accumulation of these cells in the lungs and spleen. However, they only 
acquired immunosuppressive function after the development of chemically-induced lung 
cancer (Ortiz, Lu, Ramachandran, & Gabrilovich, 2014). Additionally, in a skin 
carcinogenesis model, MDSC-like cells lacking immunosuppressive function accumulated 
in the skin and promoted tumor development (Ortiz et al., 2015). This suggests that a 
heterogeneous population of MDSC may exist, bona fide MDSC with suppressive 
capability, and MDSC-like cells that have yet to acquire immunosuppressive function. 
Only further studies will determine the purpose and function of this latter group of cells. 
MDSC-mediated immune suppression 
 
Importantly, MDSC are distinguished from their healthy-donor counterparts based 
off of their ability to suppress immune responses. There are several, often overlapping, 
mechanisms by which MDSC exert their immunomodulatory effects and they can be 
broadly separated into four categories 1) activation and expansion of the regulatory T-cell 
(Treg) population, 2) amino acid deprivation, 3) generation of oxidative stress, and 4) 
interference of lymphocyte migration and viability, discussed in more detail below (Figure 
1.2).  
First, MDSC can promote the activation and expansion of the Treg population. Treg 
can protect tumors from antitumor immunity. MDSC induce and expand Treg in vitro and 
in vivo in multiple tumor models (Adeegbe et al., 2011; B. Huang et al., 2006; MacDonald 
et al., 2005; Zoso et al., 2014). While the mechanisms are not completely understood, 
MDSC expression of CD40 and MDSC-mediated production of soluble factors such as IL-
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10 and TGFβ have been shown to play a role in Treg induction (Hoechst et al., 2008; B. 
Huang et al., 2006; Pan et al., 2010). Additionally, MDSC can activate Treg by presenting 
tumor-specific antigens in an arginase (ARG1)-dependent manner (Serafini, Mgebroff, 
Noonan, & Borrello, 2008). 
Second, MDSC can deplete amino acids in the extracellular space thereby depriving 
T-cells of amino acids they need to proliferate. For example, MDSC deplete L-arginine 
through ARG1-dependent consumption (Rodriguez et al., 2004). This results in the 
downregulation of the ζ-chain of the T-cell receptor (TCR), which is required for signal 
transduction, and also leads to T-cell arrest in G0-G1 (Rodriguez et al., 2010; Rodriguez et 
al., 2004; Rodriguez et al., 2002; Zea et al., 2004). Moreover, both MDSC and T-cells are 
unable to produce L-cystine. However, MDSC, but not naïve T-cells, express the cysteine 
transporter xc
- and are able to scavenge L-cystine from the local environment.  Naïve T-
cells must rely on antigen presenting cells (APC) to acquire L-cystine. Therefore, large 
numbers of MDSC are able to quickly deplete the local environment of L-cystine and limit 
the ability of APC to provide it to T cells (Srivastava, Sinha, Clements, Rodriguez, & 
Ostrand-Rosenberg, 2010). Finally, some MDSC also express indoleamine-pyrrole 2,3-
dioxygenase and can induce T-cell proliferative arrest by depleting the local environment 
of L-tryptophan (Munn et al., 2005; C. Smith et al., 2012). 
Third, MDSC can generate oxidative stress by producing reactive oxygen species 
(ROS) and reactive nitrogen species such as nitric oxide (NO). MDSC upregulate activity 
of NADPH oxidase to generate superoxide and other forms of ROS which can suppress T-
cell responses (Corzo et al., 2009). For example, H2O2 production in patients has been 
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shown to reduce the expression of the ζ-chain of the TCR (Schmielau & Finn, 2001). 
Additionally, different subsets of MDSC rely on different isoforms of inducible nitric oxide 
synthase to produce NO (Raber et al., 2014). NO can interfere with IL-2 receptor signaling, 
and lead to the nitration and desensitization of the TCR (Mazzoni et al., 2002; Nagaraj et 
al., 2007).  
Fourth, MDSC can interfere with lymphocyte trafficking and viability. MDSC 
express ADAM17 on their plasma membrane, resulting in decreased CD62L expression on 
the surface of naïve T-cells, preventing their recirculation to lymph nodes (Hanson, 
Clements, Sinha, Ilkovitch, & Ostrand-Rosenberg, 2009). Additionally, MDSC-derived 
peroxynitrite can modify the chemoattractant CCL2 to prevent T-cell infiltration into 
tumors (Molon et al., 2011). Furthermore, in squamous cell carcinoma patients, NO 
produced by MDSC decreases E-selectin levels, preventing T-cell adhesion to tumor 
vessels and limiting T-cell access to the tumor (Gehad et al., 2012). MDSC also express 
galectin 9, which binds to T-cell immunoglobulin and mucin domain-containing protein 3 
to induce T-cell apoptosis (Sakuishi, Jayaraman, Behar, Anderson, & Kuchroo, 2011). 
MDSC can also skew macrophages towards a pro-tumor M2 phenotype through an IL-10-
dependent mechanism (Sinha, Clements, Bunt, Albelda, & Ostrand-Rosenberg, 2007). 
Finally, MDSC can impair NK cell-mediated cytotoxicity by producing TGFβ, which 
makes NK cells more difficult to activate by decreasing expression of NK cell activating 
receptors (Elkabets et al., 2010; Mao et al., 2014).  
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Figure 1.2 Mechanisms of MDSC-mediated immunomodulation. (a) MDSC can 
promote the induction and expansion of the Treg population through mechanisms 
dependent on CD40, IL-10, TGFβ, and arginase. (b) MDSC affect T-cell activation and 
proliferation by depleting the local environment of amino acids, such as L-arginine and 
L-cystein, that T-cells cannot produce themselves. (c) MDSC generate oxidative stress 
in the form of iNOS-mediated NO and NOX-mediated superoxide that prevent the 
activation or IL-2-mediated signaling, of T-cells. (d) MDSC directly affect the 
trafficking and viability of T-cells through ADAM17 and galectin (GAL9) expression 
(D. I. Gabrilovich, Ostrand-Rosenberg, & Bronte, 2012). 
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MDSC metabolism 
 
The metabolism and function of immune cells is linked. For example, effector T-
cells rely primarily on glycolysis to produce ATP to support their rapid growth and 
proliferation, whereas memory T-cells switch to mitochondrial fatty acid oxidation (FAO) 
for their development and long term survival (Pearce & Pearce, 2013). Similarly, in in vitro 
generated MDSC, glycolysis increased concurrently with increased ARG1 activity. 
Interestingly, AMP-activated protein kinase was also activated, which can drive 
metabolism towards FAO (Hammami et al., 2012). These results were confirmed in vivo 
where, compared with splenic MDSC from a naïve or tumor-bearing mouse, both 
glycolytic and oxidative phosphorylation rates were increased in tumor-infiltrating MDSC. 
However, based on a comparison of the rates, tumor MDSC primarily used FAO and 
oxidative phosphorylation as their main metabolic pathway. In support of this finding, 
tumor-infiltrating MDSC increased fatty acid uptake and mitochondrial mass, and 
upregulated key FAO enzymes (Hossain et al., 2015). 
MDSC and metastasis 
 
In addition to their immunosuppressive function, MDSC also play a role in tumor 
metastasis. For example, in patients with non-small cell lung carcinoma, circulating M-
MDSC correlated with extrathoracic metastases (A. Huang et al., 2013). In patients with 
melanoma, increases in circulating PMN-MDSC and M-MDSC both correlated with the 
development of metastases and poor survival (Achberger et al., 2014; Weide et al., 2014). 
There is significant crosstalk between the tumor and MDSC. For example, while tumor-
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secreted factors can regulate the accumulation and expansion of MDSC, the tumor is also 
affected by chemokines, cytokines and enzymes produced by MDSC that can contribute to 
tumor cell invasion, proliferation, survival, adhesion and chemoattraction, and metastasis 
development (Figure 1.3) (Talmadge & Gabrilovich, 2013). For example, PMN-MDSC 
produce hepatocyte growth factor and TFGβ to induce epithelial-mesenchymal transition 
of primary melanoma cells in the RET-oncogene transgenic mouse model of spontaneous 
Figure 1.3 MDSC play a role in the development of metastases. Tumor cells release 
soluble factors that act systemically to affect the development of MDSC. In turn, 
MDSC can promote metastasis by promoting angiogenesis and invasion of tumor 
cells. MDSC can also protect these cells as they travel through the circulation. Finally, 
MDSC can facilitate formation of the pre-metastatic niche and extravasation of tumor 
cells into the tissue (Talmadge & Gabrilovich, 2013). 
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melanoma (Toh et al., 2011). Additionally, microRNA-494 induced by tumor-derived 
factors causes the increased production of matrix metalloproteinase 9 to facilitate tumor 
invasion (Yang Liu et al., 2012). MDSC have also been shown to facilitate tumor cell 
invasion and metastasis in mice with mammary carincomas lacking the TGFβ receptor 
through metalloproteinase activity (L. Yang et al., 2008). Moreover, MDSC contribute to 
the platelets and other myeloid cells that form heterotypic emboli to protect tumor cells 
during circulation and facilitate tumor cell arrest and extravasation (Talmadge & 
Gabrilovich, 2013).    
MDSC and the pre-metastatic niche 
 
 MDSC have also been implicated to play a role in the development of the pre-
metastatic niche. M-MDSC secreted versican in the lung of MMTV-PyMT spontaneous 
breast tumor-bearing mice to facilitate mesenchymal-epithelial transition and allow tumor 
cells to colonize the niche (Gao et al., 2012). In an orthotopic mammary tumor model, 
hypoxia in primary tumors promoted PMN-MDSC and NK cell infiltration of the lung and 
pre-metastatic niche formation (Sceneay et al., 2012). In a mouse model of hepatocellular 
carcinoma, large amounts of tissue inhibitor of metalloproteinases led to increased 
CXCL12 production, promoting CXCR4-mediated recruitment of PMN to sites for pre-
metastatic niche formation (Seubert et al., 2015). In a xenograft model, CXCL8-mediated 
recruitment of PMN by human melanoma cells helped to tether the melanoma cells to the 
vascular endothelium and promoted lung metastasis (Huh, Liang, Sharma, Dong, & 
Robertson, 2010). S100A8 and S100A9 proteins also drive the recruitment of PMN and 
PMN-MDSC to pre-metastatic sites in colon cancer, and PMN, via production of S100 
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proteins, can create a positive feedback loop resulting in the accumulation of more PMN 
in the pre-metastatic lung (Ichikawa, Williams, Wang, Vogl, & Srikrishna, 2011; 
Kowanetz et al., 2010). 
Strategies to target MDSC 
 
It is clear that inhibiting the immunosuppressive capabilities of myeloid cells will 
be important to the success of immunotherapies. Given the many different roles of MDSC 
in cancer, there are several strategies to target MDSC. In general, they strive to 1) inhibit 
mechanisms that inhibit lymphocyte activation and proliferation, 2) inhibit the generation 
of MDSC or promote the apoptosis of circulating MDSC, 3) force MDSC to mature into 
APC that can stimulate T-cell responses, 4) prevent trafficking of MDSC from the bone 
marrow to peripheral organs and to the tumor site, and 5) repolarize macrophages towards 
an M1 phenotype (D. I. Gabrilovich et al., 2012). Because there many different 
mechanisms by which MDSC exert their effects, and because inflammatory conditions can 
create “MDSC-like” cells, the most effective therapeutic strategies will likely target 
common effector molecules over one specific pathway. 
Scope of dissertation 
 
While much is known about bona fide MDSC, there is still ambiguity in regards to 
MDSC-like cells and their role in cancer progression and the development of metastases. 
Therefore, the goals of this dissertation are to gain insight into the development MDSC-
like cells and characterize their behavior. First, we determine if MDSC-like cell 
development correlates with tumor progression. Second, because the migration of MDSC 
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into peripheral tissues and the tumor site enables them to exert their immunosuppressive 
function, we determine if MDSC-like cells, which lack immunosuppressive ability, exhibit 
altered migratory behavior. Third, because many immune cells undergo metabolic 
reprogramming to facilitate their function, we investigate the metabolic profile of MDSC-
like cells in comparison to naïve PMN and bona fide MDSC. Because PMN-MDSC are 
simple and affordable to isolate from the bone marrow, and can yield sufficient cell 
numbers, the present study will focus only on PMN-MDSC-like cells. The insight we gain 
from these studies will be especially important in the context of minimal residual disease, 
a state during which a low inflammatory environment could contribute to the generation of 
MDSC-like cells that could lead to disease recurrence. 
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CHAPTER TWO: MECHANISM OF PMN MIGRATION 
 
Introduction 
 
Historically, eukaryotic cell motility has been categorized into two major forms: 
amoeboid and mesenchymal. Amoeboid migration is characterized by low adhesion, 
independence from extracellular matrix proteolytic degradation, and a rounded cell 
morphology with a highly contractile rear uropod, whereas mesenchymal migration is 
characterized as adhesion- and proteolysis-dependent, with an elongated cell tail. 
Classically, amoeboid migration is used to define the rapid migration of PMN (Hind, 
Vincent, & Huttenlocher, 2016). As described in the previous chapter, MDSC can migrate 
to the tumor site and to secondary organs to aid in the development of the pre-metastatic 
niche. As one of the aims of this dissertation is to investigate the migratory behavior of 
PMN-MDSC-like cells, in this chapter, we explore what is known already about the 
mechanisms by which PMN and PMN-MDSC migrate. 
Morphological polarization 
 
 In order to move, PMN must turn intracellularly generated forces into net cell body 
translocation by acquiring spatial asymmetry. This asymmetry, or polarized morphology 
which distinguishes the rear of the cell from the front, can be achieved even in the absence 
of a concentration gradient of stimuli (Lauffenburger & Horwitz, 1996). In this situation, 
it has been suggested that PMN break polarity by first forming the rear of the cell through 
actomyosin activity (Cramer, 2010). Interestingly, this polarization is stable, and in order 
to reverse directions PMN will make U-turns (Gerisch & Keller, 1981). The crosstalk 
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between the front and rear of the cell that maintain this polarization are poorly understood, 
but is believed to be maintained by coordinated Rho guanosine triphosphatase (GTPase) 
signaling between Rac, Cdc42 and RhoA (Hind et al., 2016). For example, Cdc42 and Rac 
are commonly thought to be restricted to the leading edge of the cell and RhoA to the rear 
(Meili & Firtel, 2003). The GTPases themselves are regulated by guanine nucleotide 
exchange factors (GEF) and GTPase-activating proteins (GAP) which maintain Rho 
GTPases in the active, GTP-bound form, or the inactive, GDP-bound form. 
Chemoattractant-mediated PMN and PMN-MDSC recruitment 
 
PMN are the first responders of the innate immune system and are recruited into 
tissues by chemoattractants. Chemotaxis is mediated by G-protein coupled receptors 
(GPCR), such as CXCR1, CXCR2, and formyl peptide receptors (FPR). In humans, 
CXCR1 predominantly interacts with CXCL8, whereas CXCR2 is more promiscuous and 
can interact with CXCL1, 2, 3, 5, 6 and 7 (Fan et al., 2007; Raghuwanshi et al., 2012). 
Homologs of these receptors have been found in mice (Swamydas et al., 2016). There are 
several chemokines that have been implicated in PMN and PMN-MDSC infiltration of 
tumors and are summarized in Table 2.1. Upon engagement of GPCR, Gαi proteins activate 
phospholipase C, resulting in the generation of diacylglycerol and inositol 1,4,5-
triphosphate signaling molecules. The Gβγ activates PI3K leading to the formation of PI 
(3,4,5)-triphosphate (PIP3) (Raghuwanshi et al., 2012). PIP3 can bind to the pleckstrin 
homology domain of GEF rendering them into the active conformation to activate Rho 
GTPases, ultimately resulting in migration (Hanna & El-Sibai, 2013).  
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Formation of the leading edge 
 
 Rac GTPase activation at the leading edge of the cell induces actin polymerization 
and leading edge protrusion (lamellipod), and it is believed that Cdc42 GTPase-mediated 
signaling steers the direction of migration (Charest & Firtel, 2007; Lam & Huttenlocher, 
2013; H. W. Yang, Collins, & Meyer, 2016). In migrating PMN, lamellipod formation is 
caused by the polymerization of monomeric globular actin (G-actin) into filamentous actin 
(F-actin). This process relies on actin nucleation factors such as Arp2/3, and nucleation 
promoting factors (NPF) such as WASP/N-WASP, WAVE, WASH, and WHAMM. 
Because the Arp2/3 complex is inherently inactive, NPF localization is critical for 
determining where polymerized actin forms. In motile cells, actin depolymerizing factor 
Chemokine Cancer Reference 
CXCL5 Non-small cell lung 
cancer 
(Kowalczuk et al., 2014) 
Melanoma (mouse) (Toh et al., 2011) 
CXCL6 Gastrointestinal tumors (Gijsbers et al., 2005) 
Tongue squamous cell 
carcinoma 
(Wang et al., 2014) 
CXCL8 Head and neck squamous 
cell carcinoma 
(Trellakis et al., 2011) 
Gastric carcinoma 
(Eck, Schmausser, Scheller, 
Brandlein, & Muller-
Hermelink, 2003) 
Bronchoalveolar 
carcinoma 
(Bellocq et al., 1998) 
Tongue squamous cell 
carcinoma 
(Wang et al., 2014) 
CCL15 Colorectal cancer (Inamoto et al., 2016) 
Table 2.1 Chemokines recruiting PMN and PMN-MDSC to the tumor. 
Adapted from (V. Kumar, Patel, Tcyganov, & Gabrilovich, 2016). 
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(ADF)/cofilin promotes lamellipod extension by severing older actin filaments to provide 
new nucleation sites for Arp2/3, and by recycling G-actin (C. T. Skau & Waterman, 2015). 
In migrating PMN, there is an increase in the total number of actin filaments, but not the 
distribution of actin filament lengths suggesting that most increased polymerization occurs 
from new nucleation sites or that severing and uncapping of actin filaments occurs in a 
coordinated fashion (Cano, Lauffenburger, & Zigmond, 1991). Another class of actin 
nucleation factors, known as formins also contribute to the formation of the lamellipod, 
however, their exact mechanism remains to be elucidated (Block et al., 2012; Colleen T. 
Skau, Plotnikov, Doyle, & Waterman, 2015; C. Yang et al., 2007). 
Contractile force generation in the uropod 
 
 The rear of the cell (uropod) generates the contractile force that is needed to 
overcome any cell adhesions and move the cell body forward. This process is primarily 
regulated by RhoA activity and myosin II. Activation of RhoA leads to the activation of 
RHO-associated coiled-coil-containing protein kinase (ROCK), that directly 
phosphorylates Ser19 on the regulatory light chain of myosin, also known as myosin light 
chain 2 (MLC2), and indirectly promotes myosin phosphorylation by phosphorylating and 
inhibiting myosin light chain phosphatase (Tybulewicz & Henderson, 2009). MLC2 
phosphorylation promotes myosin ATPase activity and results in the proper positioning of 
the myosin heads to attach to actin filaments (J. L. Tan, Ravid, & Spudich, 1992). However, 
Rac and Cdc42 can also play a role in the rear of the cell. For example, Rac is necessary 
for tail retraction during chemotaxis (Gardiner et al., 2002). Additionally, Cdc42 controls 
the redistribution of WASP, which controls clustering of CD11b in the rear of the cell, and 
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affects myosin light chain phosphorylation by ROCK (S. Kumar et al., 2012; Szczur, 
Zheng, & Filippi, 2009). Several signaling molecules localize to the uropod to drive PMN 
polarization and migration (Hind et al., 2016). For example, PDZRhoGEF, a RhoA GEF, 
localizes to the rear of PMN and acts in a positive feedback loop with RhoA, ROCK, and 
myosin II to restrict contractility to the rear of the cell (Wong, Van Keymeulen, & Bourne, 
2007). The activities of Rho GTPases and their downstream effectors are summarized in 
Figure 2.1. 
Purinergic signaling amplifies chemotactic signals 
 
 The controlled release of ATP from cells was first demonstrated in neurons. This 
process has since been discovered in immune cells and plays an important role in their 
activation. For example, autocrine ATP signaling facilitates T-cell activation at the immune 
synapse (Woehrle et al., 2010). Recent studies have shown that PMN release ATP in 
response to engagement of chemotactic receptors, and that autocrine signaling serves to 
amplify the chemotactic signal (Chen et al., 2006). This process, described in detail below, 
involves the coordinated involvement of mechanisms that allow for the release of ATP, 
metabolism of ATP, and expression of purinergic receptors that can bind to ATP. 
ATP release 
 During polarization, membrane perturbations, such as ruffling, can allow ATP to 
be released through mechanosensitive channels, such as pannexin-1 hemichannels (L. Bao, 
Locovei, & Dahl, 2004; W. G. Junger, 2008). Additionally, PMN activation results in ATP 
release through connexin and pannexin-1 hemichannels (Chen et al., 2010; Eltzschig et al., 
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2006). Pannexin-1 and connexin hemichannels are regulated by post translational 
modifications such as glycosylation and phosphorylation, however the exact role of these 
modifications is not yet elucidated (Begandt et al., 2017; Penuela, Gehi, & Laird, 2013).  
Figure 2.1 Intracellular signaling pathways mediated by Rho GTPase activation 
that result in PMN migration. Rho GTPases are regulated by guanine exchange factors 
(GEF) and GTPase activating proteins (GAP). Rac and Cd42 predominantly act at the 
leading edge of the cell. They regulate the proteins involved in the polymerization of F-
actin and formation of the lamellipod, such as Arp2/3 and DIAP3, actin nucleating 
factors, and WASP/WAVE, nucleation promoting factors. RhoA predominantly 
functions in the rear of the cell to regulate Ser19 phosphorylation of MLC2, the 
regulatory light chain of myosin II, through the activation of RHO-associated coiled-
coil-containing protein kinase (ROCK). ROCK can directly phosphorylate MLC2 or 
promote its phosphorylation by phosphorylating and inhibiting myosin light chain 
phosphatase (MLCP). Figure adapted from (Park, Chan, & Iritani, 2010).  
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ATP metabolism 
 
 Extracellular ATP can be recognized as a damage-associated molecular pattern and 
is quickly hydrolyzed by ectonucleotidases to ADP, AMP, and adenosine. There are four 
families of ectonucleotidases identified in mammalian cells. These include the 
ectonucleoside triphosphate diphosphohydrolase family (ENTPD), the ectonucleotide 
pyrophosphatase/phosphodiesterase family, the alkaline phosphatase family, and ecto-5’-
nucleotidase (CD73). PMN express the ENTPD CD39 that converts ATP to ADP and 
AMP, as well as CD73 that converts AMP to adenosine (Bours, Swennen, Di Virgilio, 
Cronstein, & Dagnelie, 2006; W. G. Junger, 2008). Finally, extracellular adenosine can be 
converted to inosine by adenosine deaminase, or removed by cellular uptake facilitated by 
concentrative or equilibrative nucleoside transporters (Wolfgang G. Junger, 2011).  
Purinergic receptors 
 
 There are three major families of purinergic receptors: 1) P1 receptors are GPCR 
that bind adenosine, 2) P2X receptors are ATP-gated ion channels that bind ATP, and 3) 
P2Y receptors are GPCR that bind ATP and ADP, as well as other nucleotides. Binding of 
ligand to these receptors can lead to receptor internalization and desensitization. Purinergic 
receptors that are expressed on PMN and their downstream effectors are summarized in 
Table 2.2 (Wolfgang G. Junger, 2011).  
Studies have shown that engagement of FPR leads to the release of ATP through 
pannexin-1 hemichannels in human PMN (Chen et al., 2010). Additionally, mitochondria, 
which are not believed to have a role in PMN beyond redox maintenance, have been 
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implicated in the initial burst of ATP that is released upon FPR activation (Y. Bao et al., 
2014). These studies have also demonstrated that P2Y2 and A3 are important mediators of  
 
extracellular ATP, and with CD39, aid in the polarization of PMN by translocating to the 
leading edge of the cell (Figure 2.2) (Chen et al., 2006; Chen et al., 2010; Corriden et al., 
2008). Moreover, P2X1-activation was shown to result in RhoA activation and 
phosphorylation of MLC2 in human and murine PMN (Lecut et al., 2009). The importance 
of purinergic signaling in chemotaxis has been confirmed using P2Y2-/-, A3-/-, P2X1-/- 
murine PMN that exhibit deficits in gradient sensing and speed (Chen et al., 2006; Lecut 
Receptor Ligands G-protein 
coupling 
Main downstream signaling event 
P2X ATP receptors 
P2X1 ATP N/A Ca2+ and Na+ influx 
P2X4 ATP N/A Ca2+ influx 
P2X5 ATP N/A Ion influx 
P2X7 ATP N/A Cation influx and pore formation 
P2Y nucleotide receptors 
P2Y1 ADP Gq/11 PLCβ activation 
P2Y2 ATP, UTP Gq/11, Gi/o PLCβ activation, cAMP inhibition 
P2Y6 UDP, UTP Gq/11 PLCβ activation 
P2Y12 ADP Gi/o cAMP inhibition 
P2Y13 ADP, ATP Gi/o cAMP inhibition 
P2Y14 UDP-glucose Gq/11 PLCβ activation 
P1 adenosine receptors 
A1 Adenosine Gi/o cAMP inhibition 
A2A Adenosine Gs cAMP production 
A2B Adenosine Gs cAMP production 
A3 Adenosine Gi/o, Gq/11 cAMP inhibition, InsP3 generation 
Table 2.2 Downstream signaling of purinergic receptors found on PMN. N/A, 
not applicable; PLCβ, phospholipase C β; cAMP, cyclic AMP; InsP3, inositol-1,4,5-
triphosphate. Adapted from (Wolfgang G. Junger, 2011). 
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et al., 2009). While signaling at the cell membrane through purinergic receptors affects 
chemotactic ability, the intracellular signaling events that link purinergic receptor 
activation to Rho GTPase activation or other factors has not yet been elucidated.  
Figure 2.2 Purinergic signaling regulates PMN chemotaxis. Formyl peptide receptor 
(FPR) activation by formyl-methionine-leucine-phenylalanine (fMLP) induces the 
release of ATP through pannexin-1 hemichannels. This results in the activation of P2Y2 
receptors, which provide signal amplification and facilitate the sensing of the 
chemotactic gradient (left). These signaling mechanisms lead to cell polarization 
(center) and translocation of pannexin-1 hemichannels, ectonucleoside triphosphate 
diphosphohydrolase 1 (ENTPD1, also known as CD39) and A3 receptors to the leading 
edge of the cell. Autocrine activation of A3 receptors promotes cell migration through 
an unknown mechanism (right) (Wolfgang G. Junger, 2011). 
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CHAPTER THREE: PMN-MDSC-LIKE CELLS RELY ON 
AUTOCRINE ATP SIGNALING TO SPONTANEOUSLY MIGRATE 
Introduction 
  
The roles of MDSC in tumor progression and metastasis are well understood. 
However, we currently know very little about MDSC-like cells. Our lab has previously 
described the expansion of MDSC-like cells, cells that lack immunosuppressive capability, 
in inflammatory conditions before cancer onset (Ortiz et al., 2014). We have also described 
their accumulation in the skin of a skin carcinogenesis model (Ortiz et al., 2014). In the 
present study, we aim to gain further insight into the characteristics of these cells. First, we 
hypothesize that PMN-MDSC-like cells develop in the context of cancer, specifically, 
during the early stages of tumor development when inflammatory conditions may support 
their development. Next, because the immunosuppressive behavior of PMN-MDSC is 
intrinsically linked to their physical migration into peripheral tissues or the tumor site to 
exert their effects, we hypothesize that PMN-MDSC-like cells exhibit altered migratory 
behavior (T. Condamine et al., 2015). Finally, because other immune cells such as T-cells, 
tumor-associated dendritic cells, and tumor-associated macrophages, and even tumor-
infiltrating MDSC, undergo metabolic reprogramming to meet the energetic demands of 
their functionality, we hypothesize that PMN-MDSC-like cells will exhibit an altered 
metabolic profile compared to naïve PMN and bona fide PMN-MDSC (Hossain et al., 
2015; V. Kumar et al., 2016; Pearce & Pearce, 2013). MDSC-like cells may represent an 
independent subset of MDSC or they may represent a stage of development that leads to 
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bona fide MDSC. By addressing these hypotheses, we hope to gain insight into the identity 
of PMN-MDSC-like cells and learn about the role of these cells in cancer to guide potential 
therapeutic interventions. 
Results 
 
PMN-MDSC-L develop in the early stages of tumor development and in transgenic 
models and are characterized by increased spontaneous migratory ability 
We isolated PMN-MDSC from the bone marrow of mice sacrificed one week after 
intravenous LL2 injection, when 0-1 tumors were visible on the lungs, and directly tested 
their immunosuppressive capability. We co-cultured them with transgenic T-cells and their 
cognate ligand, and found that they are only able to weakly suppress T-cell proliferation 
(Figure 3.1).  
Interestingly, when we tested the ability of these cells to chemotax in a 0.3um 
transwell assay for one hour in the presence of CXCL1 and fMLP, we found that the total 
number of PMN-MDSC migrated was greater than the total number of PMN at all 
concentrations of CXCL1 and fMLP (Figure 3.2A). However, we found that there was no 
difference in the fold change of PMN and PMN-MDSC to respond to CXCL1 and fMLP, 
suggesting that both PMN and PMN-MDSC are equally capable of responding to 
stimulation (Figure 3.2B). Moreover, we observed that PMN-MDSC randomly, 
spontaneously migrated more than PMN, and that this baseline level of increased motility 
accounted for enhanced PMN-MDSC chemotaxis (Figure 3.2C). We confirmed the 
presence of these cells that exhibit altered migratory behavior in the RET melanoma, KPC 
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pancreatic, and TRAMP prostate transgenic mouse models, using age-matched and PC 
mice as controls for the RET and TRAMP models and KPC model, respectively. We 
hypothesized that the slow development of tumors in transgenic models would create an 
inflammatory environment that would support their development (Figure 3.3A-C, Figure 
3.4A-C, Figure3.5A-C). We also measured the levels of chemokine receptor expression in 
the transgenic models. We found that, contrary to reports in the literature of CXCR1 
expression on murine neutrophils (Swamydas et al., 2016), PMN and PMN-MDSC from 
murine bone marrow do not express CXCR1 (Figure 3.3D, Figure 3.4D, Figure 3.5D). 
Consistent with our finding that PMN and PMN-MDSC are equally capable of responding 
to stimulation, PMN-MDSC from the RET and TRAMP model do not express increased 
levels of CXCR2 (Figure 3.3D, Figure 3.5D). While we did observe a significant increase 
in CXCR2 expression on KPC PMN-MDSC, this does not account for the increased ability 
of PMN-MDSC to spontaneously migrate (Figure 3.4D). Based on these results, we believe 
we have captured PMN-MDSC-like cell development in the early stages of tumor 
development and in transgenic models, where there is a relatively low inflammatory 
environment. These cells are characterized by weak immunosuppressive activity and 
enhanced spontaneous migration, and moving forward, we will refer to them as “PMN-
MDSC-like cells” (PMN-MDSC-L). 
Increased spontaneous migration is not observed in PMN-MDSC from the bone 
marrow of transplantable models or mice in the late stages of tumor development  
Our lab has previously shown that PMN-MDSC from the bone marrow of mice 
inoculated subcutaneously with EL4, LLC, or CT26 cells exhibit immunosuppressive 
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activity by inhibiting T-cell proliferation (data not shown). We tested the migratory 
behavior of cells from these transplantable models in a transwell assay and found that they 
spontaneously migrate at levels comparable to naïve PMN (Figure 3.6A-C). Similarly, in 
the orthotopic model, we found that PMN-MDSC from the bone marrow of mice sacrificed 
three weeks after intravenous LL2 injection, when the lungs had three or more visible 
tumors, that PMN-MDSC no longer spontaneously migrated more than PMN (Figure 
3.6D). These results suggest a correlation between migratory behavior and 
immunosuppressive function. 
PMN-MDSC-L spontaneous migration is characterized by increased speed, 
persistence time, mean squared displacement and an overall greater random motility 
coefficient compared to PMN 
To characterize the altered migratory behavior of PMN-MDSC-L cells, we tracked 
the movement of individual naïve PMN and RET PMN-MDSC-L by microscopy and 
ImageJ, and plotted the trajectory of each path, transposing the initial position of each path 
to the origin (Figure 3.7A). From these tracks, we observed that neither PMN nor PMN-
MDSC-L demonstrate a preference for directional movement, confirming that in the 
absence of stimulation, both PMN and PMN-MDSC-L move randomly. We also observed 
that PMN tracks cluster towards the origin, whereas PMN-MDSC-L spread far from the 
origin, and found that PMN-MDSC-L have a greater mean squared displacement than PMN 
(Figure 3.7B). Next, we determined that PMN-MDSC-L migrate with greater speed and an 
increased persistence time compared to PMN (Figure 3.7C,D). Finally, we calculated the 
likelihood of a cell moving randomly as defined by the random motility coefficient, 
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Random motility coefficient= (1/2) x (speed)2 x (persistence time) 
and determined that PMN-MDSC-L have an approximately 15-fold higher random motility 
coefficient compared to PMN. Collectively, these quantitative measurements support our 
findings that PMN-MDSC-L spontaneously migrate more than PMN (Figure 3.7E).  
PMN-MDSC-L utilize ATP released from the cell via pannexin-1 hemichannels to 
spontaneously migrate 
We wanted to understand the mechanism by which PMN-MDSC-L spontaneously 
migrate. Studies in human neutrophils have shown that upon engagement of formyl-peptide 
receptors by fMLP, ATP is released through pannexin-1 hemichannels. Engagement of the 
receptor also results in rearrangement of pannexin-1 hemichannels and purinergic receptors 
to the leading edge of the cell. This promotes ATP-mediated autocrine signaling that 
enhances gradient sensing and chemotaxis (Chen et al., 2006). We hypothesized that PMN-
MDSC-L may use ATP-mediated autocrine signaling as a mechanism to spontaneously 
migrate. To test this hypothesis, we first examined the effect of disrupting ATP release 
from the cell on the ability of cells to spontaneously migrate. We inhibited pannexin-1 
hemichannels using 10Panx (panx), a pannexin-1 mimetic inhibitory small peptide, and 
observed that the ability of PMN-MDSC-L from RET bone marrow to spontaneously 
migrate was abrogated (Figure 3.8A). We confirmed this finding in a second model, using 
PMN-MDSC-L from the bone marrow of mice sacrificed one week after intravenous 
injection of LL2 cells (Figure 3.8B). Furthermore, we confirmed that PMN-MDSC-L 
spontaneous migration was dependent upon pannexin-1 hemichannel-mediated ATP 
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release by treating cells with scrambled 10Panx, (scr; Figure 3.8A,B). We did not observe 
an effect on the ability of PMN to spontaneously migrate in response to pannexin-1 
hemichannel inhibition. 
To confirm that spontaneous migration is truly dependent upon ATP, we treated 
PMN-MDSC-L from the orthotopic model and PMN from naïve mice with apyrase, an 
enzyme that catalyzes the hydrolysis of ATP to yield AMP and inorganic phosphate, before 
migrating cells in a transwell assay. We found that both PMN and PMN-MDSC-L 
migration was completely abrogated (Figure 3.8C).  
PMN-MDSC-L utilize P2X1-mediated signaling to spontaneously migrate 
There are several families of ectonucleotidases expressed on the cell surface of 
mammalian cells that can hydrolyze ATP to ADP, AMP, and adenosine, and each of these 
metabolites can signal through a distinct set of purinergic receptors (Wolfgang G. Junger, 
2011). Human neutrophils have been reported to use the purinergic receptors P2X1, which 
binds ATP, and A3, which binds adenosine, to amplify chemotactic signals (Chen et al., 
2006; Lecut et al., 2009). To determine if these receptors are involved in the spontaneous 
migration of PMN-MDSC-L, we first treated cells with suramin, a pan-P2 receptor (pan-
P2R) inhibitor, and observed that only the spontaneous migration of PMN-MDSC-L was 
abrogated in transwell assays (Figure 3.9A). Next, we treated cells with NF449, a P2X1-
specific inhibitor, and found that only the ability of PMN-MDSC-L to spontaneously 
migrate was inhibited (Figure 3.9B). However, while treatment with suramin resulted in an 
approximately 75% decrease in PMN-MDSC-L spontaneous migration, treatment with 
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NF449, only resulted in an approximately 50% decrease. These results suggest that another 
P2X receptor or a P2Y receptor plays a role in the spontaneous migration of PMN-MDSC-
L mediated by ATP or its metabolites. 
Finally, we treated cells with MRS 1191, an inhibitor of A3, and did not observe a 
decrease in the total number of PMN or PMN-MDSC-L that migrated through the 
transwell, suggesting that adenosine signaling though this receptor is not required for 
PMN-MDSC-L to spontaneously migrate (Figure 3.9C). While we observed a dramatic 
decrease in spontaneous migration at the 100μM dose, a concentration that does not 
compromise the viability of the cells (data not shown), in the absence of a titrated response 
to MRS 1191, we conclude that this is likely a result of off-target effects. 
Increased PMN-MDSC-L spontaneous migration correlates with increased metabolic 
rates  
Because PMN-MDSC-L rely on extracellular ATP to spontaneously migrate, we 
hypothesized that they alter flux through their metabolic pathways to increase ATP 
production to satisfy this energetic demand. To test this hypothesis, we utilized a Seahorse 
XF Analyzer to measure the glycolytic and oxidative phosphorylation rates of PMN and 
PMN-MDSC-L from RET mice and mice sacrificed one week after intravenous injection 
of LL2 cells. In this assay, the glycolytic rate is measured by lactic acid production, and is 
thus represented as the extracellular acidification rate, and the oxidative phosphorylation 
rate is measure by the consumption of oxygen, and is thus represented as the oxygen 
consumption rate (OCR). We found that the basal level of glycolysis was significantly 
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increased in both models (Figure 3.10A). Moreover, we found that the basal level of 
oxidative phosphorylation was significantly increased only in PMN-MDSC-L isolated 
from the orthotopic LL2 model (Figure 3.10B).  
We tested the ability of these cells to respond to mitochondrial stress by inhibiting 
components of the electron transport chain. By combining inhibition of the electron 
transport chain complex V, ATP synthase, using oligomycin, and disrupting the proton 
gradient using the protonophore FCCP, we forced metabolic flux through oxidative 
phosphorylation and measured the ability of cells to maximally respire (Figure 3.10C). The 
spare respiratory capacity of cells is a measure of the ability of cells to increase metabolic 
flux through oxidative phosphorylation in the case of a sudden increase in energy demand. 
It is calculated as: 
Spare Respiratory Capacity = Maximal respiration rate - Basal respiration rate 
We found that PMN-MDSC-L from both models have an increased spare respiratory 
capacity compared to PMN (Figure 3.10D).  
Next, we isolated PMN-MDSC from the bone marrow of mice that were sacrificed 
three weeks after intravenous injection of LL2 cells, PMN-MDSC that, as we have shown 
previously, do not exhibit increased spontaneous migratory behavior compared to naïve 
PMN, and measured the basal metabolic rates, maximal respiration, and the spare 
respiratory capacity. We found that PMN-MDSC do not have increased basal glycolytic or 
oxidative phosphorylation rates compared to PMN (Figure 3.11A-C). We also found that 
the spare respiratory capacity was reduced to levels exhibited by PMN (Figure 3.11D). 
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These results lend further support to the idea that PMN-MDSC-L metabolic 
reprogramming matches the energetic need that their altered migratory behavior demands.  
PMN-MDSC-L have increased cell surface expression of the glucose transporter 
Glut1 
PMN have few mitochondria, whose main function in these cells is to maintain 
redox balance, and thus, primarily use glycolysis to generate ATP (Biswas, 2015). We have 
observed increased basal glycolytic rates in PMN-MDSC-L from two different models. We 
hypothesized three possibilities to account for these increased metabolic rates: 1) PMN-
MDSC-L increase the expression of glycolytic enzymes, 2) PMN-MDSC-L increase the 
cell surface expression of glucose transporters, or 3) PMN-MDSC-L increase glucose 
uptake. To address the first possibility, we investigated the expression of several glycolytic 
enzymes and HIF-1α, the master regulator of glycolysis, using real-time quantitative PCR 
(Iyer et al., 1998). We did not observe any differences in the expression of HIF-1α or any 
of the glycolytic enzymes investigated (Figure 3.12). 
To address the second possibility, we investigated the expression of Glut1, Glut3 
and Glut4 on PMN-MDSC-L. Glut1 expression on PMN is important for PMN function 
and is modulated by the activation state of the cells  (A. S. Tan, Ahmed, & Berridge, 1998). 
For example, Glut1 levels increase on PMN stimulated with phorbol myristate acetate to 
form extracellular traps (Rodríguez-Espinosa, Rojas-Espinosa, Moreno-Altamirano, 
López-Villegas, & Sánchez-García, 2015). Glut3 and Glut4 are primarily expressed on 
monocytes, but are of interest to us because PMN-MDSC, and potentially PMN-MDSC-L, 
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can differentiate from M-MDSC (Maratou et al., 2007; Youn et al., 2013). First, we 
measured the gene expression of Glut1 and Glut3 using real-time quantitative PCR, but did 
not observe any differences in gene expression between PMN and PMN-MDSC-L (Figure 
3.13A). Next, we measured the cell surface expression of these transporters using flow 
cytometry, and found that PMN-MDSC-L have significantly increased expression of Glut1 
compared to PMN (Figure 3.13B).  
Because we found increased expression of Glut1 on PMN-MDSC-L, we expected 
to also observe an increase in glucose uptake. Finally, to test the third possibility, we 
cultured cells in the presence of 2-NBDG, a fluorescent analog of glucose, and used flow 
cytometry to measure the uptake of glucose. Surprisingly, PMN-MDSC-L did not increase 
glucose uptake in comparison to PMN by this method (Figure 3.14). 
PMN-MDSC-L do not have an increased total pool of ATP compared to PMN 
Because we observed an increase in the basal glycolytic rates in PMN-MDSC-L, 
and an increased basal oxidative phosphorylation rate in PMN-MDSC-L in at least one 
model, we hypothesized that the total ATP pool in PMN-MDSC-L would be increased 
compared to PMN. Primarily, we hypothesized that we would be able to capture an increase 
in the amount of ATP available extracellularly. We used a luciferase-based assay to 
determine if the intracellular pool of ATP or if the amount of ATP released into the 
supernatant of cultured cells was greater in PMN-MDSC-L compared to PMN. While we 
did not observe a difference in the concentration of ATP released by PMN or PMN-MDSC-
L, we also observed great variability in the measurements (Figure 3.15A). We rationalized 
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that even small differences in the availability of ATP could contribute to spontaneous 
migration, and so we sought a more quantitative approach and used liquid chromatography-
mass spectrometry. ATP is an easily diffusive molecule that can serve as a danger signal 
in the extracellular space, and so its levels are tightly regulated by ectonucleotidases 
(Carola Ledderose et al., 2016). To increase our chances of capturing changes in free ATP 
released into the supernatant of cultured cells, we cultured the cells in the presence of the 
ectonucleotidase inhibitor ARL 67156. As an alternative approach, we also blocked ATP 
release from pannexin-1 hemichannels by treating cells with 10Panx to try to capture 
differences in intracellular ATP levels. However, using either of these approaches, we were 
unable to detect differences in the total pool of ATP available for PMN-MDSC-l (Figure 
3.15B).  
PMN-MDSC-L have increased levels of MLC2 and pMLC2 
Finally, we investigated the intracellular signaling events that ultimately result in 
movement of PMN-MDSC. Classically, PMN migration is initiated by chemokine receptor 
or integrin receptor engagement, and results in the activation of the Rho GTPases, RhoA, 
Cdc42, and Rac, which are, themselves, regulated by RhoGAP and RhoGEF. Cdc42 and 
Rac activation initiates downstream signaling that predominantly results in the formation 
of the lamellipod, and RhoA activation initiates downstream signaling that predominantly 
affects the uropod, though there can be crossover in these functions (Park et al., 2010). We 
hypothesized that aberrant activation of the Rho GTPases may account for the increased 
ability of PMN-MDSC-L to spontaneously migrate. To test this hypothesis, we measured 
the activation state of RhoA and Cdc42 in PMN and RET PMN-MDSC-L using a G-LISA. 
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This colorimetric assay uses the binding domain of a Rho-family effector protein to capture 
RhoA and Cdc42 only in the active, GTP-bound, form. We did not observe significant 
activation of RhoA or Cdc42 in PMN-MDSC-L compared to PMN (Figure 3.16A,B). 
Classically, GTPase activation results in the activation of kinases, such as PAK or 
ROCK, and further signal amplification through the activation of downstream kinases. We 
hypothesized that aberrant activation of these kinases would bypass the need for GTPase 
activation and could explain how PMN-MDSC-L are able to spontaneously migrate. 
Instead of determining the activation state of individual kinases, we sought to observe 
changes in the terminal effects of these signaling pathways, such as the polymerization of 
F-actin or actomyosin contraction. Therefore, we first measured levels of F-actin in cells 
using phalloidin, a phallotoxin derived from the death cap mushroom that tightly binds to 
and stabilizes F-actin. We found that both PMN and PMN-MDSC-L were equally 
stimulated by CXCL1 and fMLP and that in the absence of stimulation, PMN and PMN-
MDSC-L generated similar amounts of F-actin (Figure 3.17A,B).  
Based on these results, we hypothesized that PMN-MDSC-L and PMN are 
equivalently primed to spontaneously migrate, however, aberrant action in the uropod, such 
as increased actomyosin contraction, could explain the increased motility of PMN-MDSC-
L. The preceding event to actomyosin contraction is the phosphorylation of myosin light 
chain 2 (MLC2) on Ser19 (pMLC2), an event that allows for the proper arrangement of 
myosin heads to facilitate contraction. To investigate this possibility, we measured pMLC2 
by western blot, and interestingly, we found that not only were pMLC2 levels increased in 
PMN-MDSC-L, but total MLC2 levels were also increased (Figure 3.18).  
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Collectively, these experiments have demonstrated that relatively low 
inflammatory conditions in cancer results in the production of PMN-MDSC-L that exhibit 
enhanced spontaneous migratory behavior.  Furthermore, we have identified pannexin-1 
hemichannel-mediated ATP release and P2X1 engagement as the mechanism by which 
PMN-MDSC-L spontaneously migrate. We have also shown that PMN-MDSC-L alter 
their metabolic profile to meet the energetic demands of their altered migratory behavior 
by increasing cell surface expression of Glut1 and flux through glycolytic pathways (Figure 
3.19). We discuss the implications of these findings in the next chapter. 
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Figure 3.2 
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Figure 3.4 
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Figure 3.5 
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Figure 3.6 
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Figure 3.7 
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Figure 3.8 
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Figure 3.9 
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Figure 3.10 
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Figure 3.11 
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Figure 3.12 
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Figure 3.13 
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Figure 3.14 
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Figure 3.15 
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Figure 3.16 
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Figure 3.17 
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Figure 3.18 
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Figure 3.19 
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Figure legends 
Figure 3.1 PMN-MDSC-like cells from an orthotopic model in the early stage of 
tumor development are weakly immunosuppressive. Naïve PMN and PMN-MDSC 
from mice sacrificed one week after intravenous injection of LL2 cells were co-cultured 
with PMEL splenocytes and gp100 for 48h and spiked with 3H-thymidine for 8h to measure 
T-cell proliferation (N=6). Control wells were plated with only PMEL splenocytes +/- 
gp100. Data are represented as counts per million (CPM) and the dashed line indicates the 
proliferation of the positive control. 
Figure 3.2 PMN-MDSC-like cells from an orthotopic model in the early stage of 
tumor development spontaneously migrate more than PMN. (A) PMN-MSDC were 
isolated from the bone marrow of mice sacrificed one week after intravenous injection of 
LL2 cells. Total number of PMN and PMN-MDSC that migrated in transwell assay for 1h, 
37°C, 5% CO2 with varying doses of CXCL1 and fMLP. (B) Fold change in response to 
CXCL1 and fMLP. (C) Total number of cells that spontaneously migrate (Naïve N=5, 
LL2=7). 
Figure 3.3 RET PMN-MDSC-like cells spontaneously migrate more than PMN. (A) 
Total number of PMN and PMN-MDSC that migrated in transwell assay for 1h, 37°C, 5% 
CO2 with varying doses of CXCL1 and fMLP. (B) Fold change in response to CXCL1 and 
fMLP. (C) Total number of cells that spontaneously migrate (N=5). (D) Cell surface 
expression of CXCR1 and CXCR2 (N=5).  
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Figure 3.4 KPC PMN-MDSC-like cells spontaneously migrate more than PMN. (A) 
Total number of PMN and PMN-MDSC that migrated in transwell assay for 1h, 37°C, 5% 
CO2 with varying doses of CXCL1 and fMLP. (B) Fold change in response to CXCL1 and 
fMLP. (C) Total number of cells that spontaneously migrate (N=7). (D) Cell surface 
expression of CXCR1 and CXCR2 (N=6).  
Figure 3.5 TRAMP PMN-MDSC-like cells spontaneously migrate more than PMN. 
(A) Total number of PMN and PMN-MDSC that migrated in transwell assay for 1h, 37°C, 
5% CO2 with varying doses of CXCL1 and fMLP. (B) Fold change in response to CXCL1 
and fMLP. (C) Total number of cells that spontaneously migrate (Naïve N=3, TRAMP 
N=5). (D) Cell surface expression of CXCR1 and CXCR2 (Naïve N=2, TRAMP N=4).  
Figure 3.6 PMN-MDSC from transplantable models or from an orthotopic model in 
the late stage of tumor development do not spontaneously migrate more than PMN. 
Total number of PMN-MDSC from (A) EL4 tumor-bearing mice, (B) LLC tumor-bearing 
mice, (C) CT26 tumor-bearing mice, and (D) from mice sacrificed three weeks after 
intravenous injection of LL2 cells and naïve PMN were spontaneously migrated in a 
transwell assay for 1h, 37°C. For transplantable models, mice were sacrificed when the 
tumor diameter reached between 1.5-2.0cm. 
Figure 3.7 Characteristics of PMN-MDSC-L spontaneous migration. (A) Trajectories 
of individual PMN and RET PMN-MDSC-L were plotted with the starting point transposed 
to the origin. The (B) mean squared displacement, (C) speed, (D) persistence time, and (E) 
random motility coefficient were calculated from at least 80 cells.  
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Figure 3.8 Extracellular ATP is required for PMN-MDSC-L spontaneous migration. 
PMN-MDSC-L from (A) RET mice (N=5) and (B) mice sacrificed one week after 
intravenous injection of LL2 cells (N=4) and naïve PMN were pre-treated with 100μM 
10Panx (panx) or scrambled 10Panx (scr) prior to migration in a transwell assay for 1h, 37°C, 
5% CO2. (C) PMN-MDSC-L (N=10) from mice sacrificed one week after intravenous 
injection of LL2 cells and naïve PMN (N=8) were pretreated with 10units/ml apyrase prior 
to migration in a transwell assay for 1h, 37°C, 5% CO2. 
Figure 3.9 PMN-MDSC-L utilize the P2X1 receptor to spontaneously migrate. PMN-
MDSC-L from mice sacrificed one week after intravenous injection of LL2 cells and naïve 
PMN were pre-treated with (A) 10μM suramin (pan-P2R inhibitor) (Naïve N=6, LL2 N=7), 
(B) NF449 (P2X1-specific inhibitor) (Naïve N=7, LL2 N=8), or (C) various doses of MRS 
1191 (A3R inhibitor) (N=5) prior to migration in a transwell assay for 1h, 37°C, 5% CO2. 
Figure 3.10 PMN-MSDC-L from transgenic mice or from an orthotopic model in the 
early stage of tumor development have increased metabolic rates compared to PMN. 
PMN-MDSC-L from RET mice and mice sacrificed one week after intravenous injection 
of LL2 cells and naïve mice were analyzed on a Seahorse XF Analyzer. The (A) glycolytic 
rate and (B) oxidative phosphorylation rates were determined. (C) The changes in oxidative 
phosphorylation rates upon treatment with mitochondrial inhibitors A, 5μM oligomycin, 
B, 1μM FCCP, and C, a combination of 0.75μM Rotenone and 1μM Antimycin A were 
measured, and the (D) spare respiratory capacity was determined (N=3).  
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Figure 3.11 PMN-MDSC from an orthotopic model in the late stage of tumor 
development do not have altered metabolic rates compared to PMN. PMN-MDSC 
from mice sacrificed three weeks after intravenous injection of LL2 cells and naïve mice 
were analyzed on a Seahorse XF Analyzer. The (A) glycolytic rate and (B) oxidative 
phosphorylation rates were determined. (C) The changes in oxidative phosphorylation rates 
upon treatment with mitochondrial inhibitors A, 5μM oligomycin, B, 1μM FCCP, and C, 
a combination of 0.75μM Rotenone and 1μM Antimycin A were measured, and the (D) 
spare respiratory capacity was determined (N=3). 
Figure 3.12 PMN-MDSC-L do not exhibit transcriptional changes HIF-1α or enzymes 
in the glycolytic pathway. Real-time quantitative PCR was conducted on naïve PMN and 
RET PMN-MDSC-L to investigate expression of proteins involved in glycolysis Gene 
expression was normalized to β-actin (N=3). 
Figure 3.13 PMN-MDSC-L have increased cell surface expression of Glut1. (A) Real-
time quantitative PCR was conducted on naïve PMN and RET PMN-MDSC-L to 
investigate Glut1 and Glut3 gene expression (N=3). (B) The cell surface expression of 
Glut1 (Naïve N=9, LL2 N=11), Glut3 (Naïve N=5, LL2 N= 7), and Glut4 (Naïve N=6, 
LL2 N=7) on naïve PMN and PMN-MDSC-L from mice sacrificed one week after 
intravenous injection of LL2 cells was determined. 
Figure 3.14 PMN-MDSC-L do not increase glucose uptake. Naïve PMN (N=11) and 
PMN-MDSC-L (N=12) from mice sacrificed one week after intravenous injection of LL2 
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cells were incubated with 250µM 2-NBDG for 1h at 37°C, 5% CO2, after which glucose 
uptake was determined by flow cytometry. 
Figure 3.15 PMN-MDSC-L do not increase total ATP production. (A) Intracellular 
ATP levels (left) and levels of ATP released into the supernatant of naïve PMN and RET 
PMN-MDSC-L cultured for 1h, 37°C, 5% CO2 (right), were determined using a luciferase-
based assay (N=7). (B) Intracellular ATP levels of naïve PMN and PMN-MDSC-L from 
mice sacrificed one week after intravenous injection of LL2 cells treated with 100μM 
10Panx (left) and levels of ATP released into the supernatant of cells cultured with 100μM 
ARL 67156 for 1h, 37°C, 5% CO2 (right), were determined by LC-MS/MS analysis (N=3). 
Figure 3.16 PMN-MDSC-L do not have increased GTPase activation. The activation 
of (A) RhoA (N=4) and (B) Cdc42 (N=2) in naïve PMN and RET PMN-MDSC-L were 
determined by G-LISA. 
Figure 3.17 PMN-MDSC-L do not have increased F-actin levels. (A) The amount of 
polymerized F-actin in naïve PMN and RET (top, N=3), KPC (middle, PC N=3, KPC 
N=4), and TRAMP (bottom, Naïve N=3, TRAMP N=5) PMN-MDSC-L was measured in 
response to stimulation with various doses of CXCL1 and fMLP by phalloidin and flow 
cytometry. (B) The unstimulated levels of F-actin from the experiments in (A) and from 
naïve PMN and PMN-MDSC-L from mice sacrificed one week after intravenous injection 
of LL2 cells were determined (N=4).  
Figure 3.18 PMN-MDSC-L have increased levels of pMLC2. Naïve PMN and PMN-
MDSC-L from mice sacrificed one week after intravenous injection of LL2 cells were 
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isolated and immediately snap frozen. The levels of pMLC2, total MLC2 and β-actin were 
determined by western blot analysis (N=3). 
Figure 3.19 Model of PMN-MDSC-L spontaneous migration. PMN-MDSC-L increase 
the expression of the Glut1 glucose transporter on the cell surface and have an increased 
glycolytic rate and spare respiratory capacity (SRC). PMN-MDSC-L rely on pannexin-1 
hemichannel-mediated release of ATP to spontaneously migrate. Autocrine ATP signaling 
occurs at least partially through the P2X1 purinergic receptor, suggesting a role for other 
P2Y or P2X receptors in this process. Finally, PMN-MDSC-L increase phosphorylation of 
MLC2 at Ser19 (pMLC2) to drive actomyosin contraction and motility.  
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Methods 
Transgenic mouse models. WT C57BL/6 or Balb/c female 6-8 week old mice were 
obtained from the National Cancer Institute or Charles River Laboratory. TRAMP 
transgenic and age-matched control mice were provided by Dr. Lucia Languino, Thomas 
Jefferson University. KPC and PC mice were provided by Dr. Robert Vonderheide, 
University of Pennsylvania. RET mice were obtained from Dr. Viktor Umansky, German 
Cancer Research Center, and the colony maintained in-house.  
Transplantable and orthotopic mouse models. EL4 lymphoma, Lewis lung carcinoma 
(LLC), and CT26 colon carcinoma cells were obtained from ATCC. LL2 cells were 
obtained from Moffitt Cancer Center. For transplantable models, 0.5x106 tumor cells were 
injected in 100µl PBS subcutaneously in the flank of mice. For the orthotopic model, 
0.1x106 LL2 cells were injected in 100µl PBS intravenously through the tail vein. Tumors 
developed three weeks.  
Murine bone marrow, PMN, and PMN-MDSC isolation. The muscle and connective 
tissue was removed from the femurs and tibia of euthanized mice. Bone marrow was 
flushed from the bones with PBS using a 25-gauge needle (Fisher Scientific, Cat#: 14-
826AA), and red blood cells were lysed using Ammonium-Chloride-Potassium (ACK) 
lysing buffer. Cells were filtered through 70µm cell strainer (Fisher Scientific, Cat#: 
087712) and resuspended in MACS buffer (0.5% heat-inactivated FBS and 2mM EDTA 
in PBS, filtered) for further use. PMN were isolated from the bone marrow of naïve mice 
and PMN-MDSC were isolated from the bone marrow of tumor-bearing mice: Bone 
marrow cells were incubated with Ly6G+-biotin beads (Miltenyi Biotec, Cat#: 130-101-
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884), anti-streptavidin beads (Miltenyi Biotec, Cat#: 130-048-101), and isolated following 
the manufacturer’s protocol. 
Transwell assays for migration and chemotaxis. Unstimulated migration and 
chemotaxis was measured using a 3µm pore transwell system (Neuro Probe Inc, Cat#: 101-
3 or Sigma-Aldrich, Cat#: CLS3415). Advanced RPMI with CXCL1 (BioLegend, Cat#: 
573702) or fMLP (Sigma-Aldrich, Cat#: F3506) was placed in the bottom of the transwell, 
as indicated. Cells were incubated with pannexin inhibitor (10Panx; Tocris, Cat#: 3348), 
scrambled 10Panx (Tocris, Cat#: 3708), pan-P2XR inhibitor suramin (R&D Systems, Cat#: 
1472), P2X1 inhibitor NF 449 (Tocris, Cat#: 1391), A3R inhibitor MRS 1191 (Santa Cruz, 
Cat#: sc-253056), ectonucelotidase inhibitor ARL 67156 (Sigma-Aldrich, Cat#: A265), or 
apyrase (New England Biolabs, Cat#: M0398L) in Advanced RPMI for 10min prior to 
being plated on top of the filter, 0.1x106 or 0.5x106 cells for the Neuro Probe system or 
Sigma-Aldrich system, respectively, and placed at 37°C, 5% CO2 for 1 hour. Cells that 
migrated through the transwell were counted by hemocytometer.  
Chemokine receptor and glucose transporter measurement. Total bone marrow cells 
were stained with LIVE/DEAD Fixable Aqua Dead cell stain (AQUA; Thermo Fisher, 
Cat#: L34966), CD11b-BV421 (BioLegend, Cat#: 101236), Ly6G-APC (Becton-
Dickinson, Cat#: 560599), and CXCR1-PE (R&D Systems, Cat#:FAB8628P), CXCR2-PE 
(R&D Systems, Cat#: FAB2164P), Glut1 (Novus Biologicals, Cat#: NB110-39113), Glut3 
(Abcam, Cat#: ab136180), or Glut4 (Novus Biologicals, Cat#: NBP1-49533), washed in 
PBS, run on a flow cytometer (LSR II 14-color, Becton-Dickinson), and analyzed using 
FlowJo.  
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T-cell suppression assay. PMN and PMN-MDSC were co-cultured with splenocytes from 
transgenic PMEL mice at the indicated dilutions and T-cells were stimulated to proliferate 
using PMEL-specific peptide gp100 for 48 hours. Cells were pulsed with 3H-Thymidine 
(PerkinElmer, 1µCi/well) for 8 hours, and 3H-Thymidine uptake was measured using a 
liquid scintillation counter and expressed as counts per million (CPM). 
Live-cell imaging. The wells of a 6-well plate were coated with 50μg/ml fibronectin 
(Sigma-Aldrich, Cat#: F1141) and washed with PBS. 0.5 x 106 cells were plated per well 
in Advanced RPMI (Thermo Fisher, Cat#: 12633-012) and placed in a 37°C, 5% CO2 
incubator for 15 minutes to allow the cells to attach. The wells were gently washed with 
PBS one time to remove non-adherent cells and Advanced RPMI was added to the wells. 
Cells were placed onto a motorized stage and observed using a Nikon Eclipse TE300 
fluorescence microscope maintained in an environment of 37°C and 5% CO2. Images were 
captured every 30 seconds over the course of 15 minutes from at least four different fields.  
Measurement of cell trajectories and mean-squared displacements. Cell movement 
was tracked using the ImageJ plugin Manual Tracking. ImageJ and the plugin are both 
freely available through the NIH website (http://rsbweb.nih.gov/ij/). The centroid of the 
cell was considered to represent the cell position. Time lapse microscopy was used and 
images were taken every 30 seconds over a total of 15 minutes. The result was a series of 
(x,y) positions with time for each cell. The net displacement during the ith 30 second 
increment, Di, was calculated as the difference of the position from the beginning to the 
end of that time step.  The mean-squared displacement, ⟨𝐷2(𝑡)⟩, over time was calculated 
using the method of non-overlapping intervals (Dickinson & Tranquillo, 1993).  Speed, S, 
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can be considered as the total path length over time and persistence time, P, is the time a 
cell remains moving without changing direction.  S and P were obtained by fitting these to 
the persistent random walk equation ⟨𝐷2(𝑡)⟩ = 2𝑆2[𝑡 − 𝑃(1 − 𝑒−𝑡∕𝑃)]  where t is the time 
interval, using a non-linear least squares regression analysis (Dunn, 1983). The random 
motility coefficient (µ) is then calculated as  𝜇 =
1
2
𝑆2𝑃 (Ford & Lauffenburger, 1991). 
Seahorse assay. Metabolic rates were determined using the Seahorse XF24 and XF96 Flux 
Analyzers (Seahorse Biosciences) following the manufacturer’s protocol. Briefly, the 
microplate was coated with 22.4µg/ml Cell-Tak (Fisher, Cat#: 354240) using 200mM 
sodium bicarbonate. 1.2x106 or 0.4x106 cells were seeded per well immediately after 
isolation in 50µl and 80µl of unbuffered RPMI (Sigma-Aldrich, Cat#: R1383) for the XF24 
and XF96 analyzers, respectively. The plate was incubated for 30min at 37°C to allow the 
cells to settle into a monolayer. Unbuffered RPMI was gently added to the wells without 
disturbing the monolayer to bring the assay volume to 675µl and 180µl for the XF24 and 
XF96 analyzer, respectively. The basal oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) was measured, in addition to rate changes upon treatment with 
5µM oligomycin (Sigma-Aldrich, Cat#: 75351), 1µM FCCP (Sigma-Aldrich, Cat#: 
C2920), and 0.75µM Rotenone and 1µM Antimycin A (Sigma-Aldrich, Cat#: R8875 and 
A8674, respectively). 
Real-time quantitative PCR. Cells were lysed and RNA was isolated using the E.Z.N.A. 
total RNA purification kit (Omega Bio-Tek, Cat#: R6834-02). Reverse transcription was 
performed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems 
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Inc. #4368813). Quantitative PCR was then performed using Sybr Green PCR Master Mix 
(Applied Biosystems Inc. #4368706) on an ABI 7500 Fast instrument, using the following 
primers: 
Glut1 
Fwd: AGCCCTGCTACAGTGTAT 
Rev: AGGTCTCGGGTCACATC 
Glut3 
Fwd: ATGGGGACAACGAAGGTGAC 
Rev: CAGGTGCATTGATGACTCCAG 
HIF1α 
Fwd:  TCTCGGCGAAGCAAAGAGTC 
Rev:  AGCCATCTAGGGCTTTCAGATAA 
Hexokinase 
Fwd: ATGATCGCCTGCTTATTCACG 
Rev: CGCCTAGAAATCTCCAGAAGGG 
Phosphofructokinase 
Fwd: CATCGCCGTGTTGACCTCT 
Rev: CCCGTGAAGATACCAACTCGG 
GAPDH 
Fwd:  CCCTTAAGAGGGATGCTGCC 
Rev:  ACTGTGCCGTTGAATTTGCC 
Phosphoglycerate 
kinase 
Fwd:  CCCAGAAGTCGAGAATGCCTG 
Rev:  CTCGGTGTGCAGTCCCAAA 
Enolase 
Fwd:  AGTACGGGAAGGACGCCACCA 
Rev:  GCGGCCACATCCATGCCGAT 
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Pyruvate kinase 
Fwd:  GCCGCCTGGACATTGACTC 
Rev:  CCATGAGAGAAATTCAGCCGAG 
β-actin 
Fwd: CCTTCTTGGGTATGGAATCCTGT 
Rev: GGCATAGAGGTCTTTACGGATGT 
Glucose uptake assay. PMN and PMN-MDSC (1x106 cells) were stained with AQUA, 
washed in PBS, and cultured in MACS buffer with 250µM 2-(N-(7-Nitrobenz-2-oxa-1,3-
diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG; Thermo Fisher, Cat#: N13195) for 1 hour 
at 37°C, 5% CO2. Cells were washed in PBS and fixed with 4% paraformaldehyde in PBS 
before flow cytometry and FlowJo analysis. 
ATP measurement. The total pool of intracellular ATP and the levels of ATP released 
into the supernatant of cultured cells (1x106 cells/ml, 1h, 37°C) was measured by ATP 
Determination Kit (Thermo Fisher, Cat#: A22066) following the manufacturer’s protocol. 
Intracellular ATP was measured by centrifuging the cells at 1500rpm, 5min, removing the 
supernatant and permeabilizing the cells in 1% TritonX-100 in PBS, supplemented with 
protease inhibitors. A second approach to measuring ATP levels utilized LC-MS/MS. In 
this method, cells were incubated in the presence of 10Panx to measure levels of 
intracellular ATP, and cells were incubated in the presence of ARL 67156 to measure levels 
of ATP released into the supernatant of cultured cells. Nucleotides were extracted from the 
supernatant and cell pellet as described (Kochanowski et al., 2006). Briefly, nucleotides 
were precipitated from the supernatant and cell pellet using 1M and 0.5M perchloric acid, 
respectively. The supernatants containing ATP were neutralized with 2.5M potassium 
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hydroxide in 1.5M potassium phosphate, centrifuged to remove the potassium perchlorate 
precipitate, filtered, and stored at -80°C before analysis. LC-MS/MS analysis was carried 
out using a Q-trap5500 coupled to a Shimadzu UHPLC system by the Wistar Institute 
Proteomics and Metabolomics Core Facility. Metabolites were normalized to heavy 
internal standards added to the samples and peak identification was confirmed by injecting 
a solution of pure ATP.  
GTPase activation assay. RhoA and Cdc42 activity was determined using G-LISA™ 
activation Assay Kits (Cytoskeleton Inc., Cat#: BK124 and BK127, respectively) 
following the manufacturer's protocol. Briefly, samples were added to the wells of a G-
LISA plate coated with Rho/Cdc42-GTP-binding protein. The plate was washed and 
incubated with anti-RhoA/Cdc42 primary antibody, incubated with HRP-conjugated 
secondary antibody and detected by a microplate spectrophotometer reader at 490nm.  
F-actin measurement. Total bone marrow cells were stained with AQUA, CD11b-
BV421, and Ly6G-APC. Cells were washed and stimulated with doses of CXCL1 and 
fMLP in Advanced RPMI for the time points indicated. Cells were immediately fixed and 
permeabilized using Cytofix/Cytoperm Solution (Becton-Dickinson, Cat#: 554722) and 
washed in Perm/Wash Buffer (Becton-Dickinson, Cat#: 554723) following the 
manufacturer’s protocol. Cells were stained with 1 unit of Phalloidin-AF488 (Thermo 
Fisher, Cat#: A12379) for 20min at 4°C, washed in Perm/Wash Buffer, run on a flow 
cytometer, and analyzed using FlowJo.  
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Western blot. Cells were lysed in RIPA buffer (Sigma-Aldrich, Cat#: R0278) 
supplemented with protease inhibitors (Sigma-Aldrich, Cat#: P8340), phosphatase 
inhibitors (Sigma-Aldrich, Cat#: P5726 and P0044) and 1mM PMSF, and cleared by 
centrifugation. Protein concentration was determined by Bio-Rad Protein Assay Dye 
Reagent (Bio-Rad, Cat#: 500-0006) following the manufacturer’s protocol. Lysates were 
diluted in reducing Laemmli buffer (Fisher Scientific, Cat#: NC9566545), denatured at 
95°C, run on 12% polyacrylamide gels, transferred to PVDF membrane, blocked in 5% 
milk, and incubated with primary antibodies for pMLC2, MLC2, and β-actin (Cell 
Signaling Cat#: 3671S, 3672S, and 5125S, respectively) at 4°C, overnight. 
Immunoreactive bands were developed using horseradish peroxidase-conjugated 
secondary antibodies (Santa Cruz, Cat#: SC-2301) and enhanced chemiluminescent 
substrate (Thermo Scientific, Cat#: 32209, or GE Healthcare, Cat#: RPN2232). 
Statistics. Unless otherwise indicated, data are presented as mean ± SEM. An unpaired, 2-
tailed t-test was used to determine significance, and p values less than 0.05 were considered 
significant (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). All modeling and analysis 
was performed using Graphpad Prism v 6.07. 
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
 
Discussion 
 In the preceding chapter, we have demonstrated that MDSC-like cells, PMN-
MDSC-L, develop in the early stages of tumor development and exhibit an enhanced ability 
to spontaneously migrate. We have characterized this altered migratory behavior and 
identified a mechanism by which PMN-MDSC-L are able to spontaneously migrate. 
Moreover, we have demonstrated that PMN-MDSC-L undergo metabolic reprogramming. 
These findings further our understanding of MDSC-like cells and MDSC development. 
The remainder of this chapter discusses the implications of these findings and provides 
ideas to expand on these observations. 
Identification of characteristics of PMN-MDSC-L in cancer 
We began our studies by demonstrating that PMN-MDSC-L are characterized by 
poor immunosuppressive capability and an enhanced ability to spontaneously migrate in 
the context of cancer. We found that while PMN and PMN-MDSC-L are both equally able 
to respond to stimulation with CXCL1 or fMLP, PMN-MDSC-L spontaneously migrated 
2-3 fold times more than PMN. We have shown that PMN-MDSC-L motility is 
characterized by increased speed, persistence time, mean squared displacement and an 
overall increased random motility coefficient compared to PMN. Collectively, these 
findings demonstrate that PMN-MDSC-L are predisposed to random walk.  
Significantly, we have shown that PMN-MDSC-L develop in the early stages of 
tumor development and in transgenic mouse models, but not in transplantable models or in 
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the late stages of tumor development. We believe that because transplantable models force 
a highly inflammatory environment in a short amount of time, we may quickly bypass the 
stage where we are able to capture PMN-MDSC-L. In comparison, transgenic models, 
which also generate an inflammatory environment, develop tumors relatively slowly, 
allowing us to capture this distinct cell population.  
Mechanism of PMN and PMN-MDSC-L spontaneous migration 
To investigate the mechanism by which PMN-MDSC-L spontaneously migrate, we 
focused on studies investigating neutrophil chemotaxis. Several studies have shown that 
upon engagement of the FPR, ATP can be released via pannexin-1 hemichannels to act in 
an autocrine fashion by engaging purinergic receptors such as P2X1, P2Y2, and A3 (Chen 
et al., 2006; Lecut et al., 2009). Moreover, autocrine purinergic signaling has been shown 
to be important in other immune cells suggesting this may be a pervasive phenomenon. For 
example, pannexin-1 hemichannel-mediated ATP release and signaling through P2X1 and 
P2X4 has also been shown to be important for T-cell activation at the immune synapse 
(Woehrle et al., 2010). We found that PMN-MDSC-L spontaneous migration is dependent 
upon pannexin-1 hemichannel-mediated ATP release and, at least partially, on P2X1-
mediated signaling. However, though reported to be important for murine neutrophil 
chemotaxis, we did not find a role for A3 in PMN-MDSC-L spontaneous migration (Chen 
et al., 2006).  
These studies identified some distinct characteristics by which PMN and PMN-
MDSC-L spontaneously migrate. First, our data clearly show that the ability of naïve PMN 
to spontaneously migrate is significantly affected by apyrase treatment, but not affected by 
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pannexin-1 hemichannel inhibition. This suggests that PMN use a different mechanism to 
release ATP. In fact, a study had demonstrated that murine PMN can utilize connexin 
hemichannels to release ATP (Eltzschig et al., 2006). Second, we have observed that PMN 
spontaneous migration is unaffected by pan-P2R or P2X1 inhibition. This suggests that 
while PMN also rely on extracellular ATP to spontaneously migrate, they must utilize a 
different set of purinergic receptors for this function.  
Stimulation of P2X1 with nonhydrolyzable ATP has been shown to selectively 
activate RhoA in both human and mouse neutrophils, resulting in phosphorylation of 
MLC2 (Lecut et al., 2009). Moreover, studies in mouse neutrophils have shown that fMLP-
induced chemotaxis depends on Cdc42-mediated activation of mixed lineage kinase 3 
(Polesskaya et al., 2014). However, our studies have shown that PMN-MDSC-L and PMN 
have similar levels of RhoA and Cdc42 activation. Interestingly, we found that PMN-
MDSC-L express more total MLC2 and have increased levels of pMLC2. This suggests 
that 1) PMN-MDSC-L are fundamentally different than PMN, and 2) that an alternative 
signaling pathway downstream of P2X1 activation can result in pMLC2. Moreover, we 
found similar levels of F-actin in PMN and PMN-MDSC-L suggesting that PMN may be 
equivalently primed to spontaneously migrate, but activation of alternative signaling 
pathways that lead to pMLC2 in PMN-MDSC-L ultimately results in spontaneous 
migration. We speculate on a potential intracellular signaling connection between P2X1 
and pMLC2 in the next section. 
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Metabolic reprogramming of PMN-MDSC-L 
Several immune cells have been shown to alter their metabolism to support their 
function. For example, tumor-associated macrophages and tumor-associated dendritic cells 
both undergo metabolic changes due to the tumor microenvironment that enhance their 
pro-tumoral effects. Additionally, compared to effector T cells, memory T-cells undergo 
metabolic changes to sustain their longevity (V. Kumar et al., 2016; Pearce & Pearce, 
2013). Similarly, in in vitro differentiated MDSC, increases in glycolysis correlated with 
increases in ARG1 expression (Hammami et al., 2012). In an in vivo study, compared to 
splenic MDSC, tumor-infiltrating MDSC were shown to switch to a metabolic pathway 
that preferred FAO and increased flux through oxidative phosphorylation (Hossain et al., 
2015). Increased flux though the electron transport chain would result in the generation of 
ROS, supporting the immunosuppressive function of tumor-infiltrating MDSC (Yuanbin 
Liu, Fiskum, & Schubert, 2002). However, we found that PMN-MDSC-L have an 
increased basal glycolytic rate compared to naïve PMN, though we did observe an increase 
in oxidative phosphorylation in one of our models. We propose that increased flux through 
the glycolytic pathway would quickly generate ATP to support the rapid and dynamic 
process of spontaneous cell migration. 
We found that the metabolic profile of PMN-MDSC from the bone marrow of mice 
sacrificed three weeks after intravenous injection of LL2 cells was similar to the metabolic 
profile of naïve PMN. These results are in contrast to the observations of Hossain, et al that 
showed that tumor-infiltrating MDSC utilize FAO. However, it is important to note that 
Hossain et al. investigated the metabolic profile of the total MDSC population, not 
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specifically of PMN-MDSC. Moreover, we studied the metabolic profile of PMN, PMN-
MDSC-L, and PMN-MDSC coming from the bone marrow, not the tumor 
microenvironment or the spleen, which may account for the differences in our 
observations.  
To investigate what drives the changes in the metabolic rates, we found that there 
were no differences in the gene expression of HIF-1α, glycolytic enzymes, or the glucose 
transporters Glut1 and Glut3. This was an interesting finding as HIF-1α has been shown to 
increase the expression of ARG1 and iNOS to increase the immunosuppressive activity of 
MDSC, and may explain why the PMN-MDSC-L were not strongly immunosuppressive 
(Corzo et al., 2010). However, PMN-MDSC-L did increase cell surface expression of the 
glucose transporter Glut1 compared to PMN. Inconsistent with these results, however, is 
the observation that PMN-MDSC-L do not increase their glucose uptake. We believe this 
is due to limitations associated with the probe used to make these measurements. 2-NBDG 
is a fluorescent analog of glucose, however, upon uptake can be phosphorylated by 
hexokinase, and degraded to non-fluorescent products (Jung, Ha, Zheng, Chang, & 
Williams, 2011). We are exploring an alternative approach to investigate this discrepancy, 
discussed further in the next section. 
We also found that PMN-MDSC-L have an increased spare respiratory capacity 
compared to PMN. This means that means that under stressful conditions, PMN-MDSC-L 
are able to increase flux through the oxidative phosphorylation pathway to meet energetic 
demands. However, PMN have been shown to rely primarily on glycolysis as their main 
method of ATP production (Borregaard & Herlin, 1982). Consistent with this report, 
previous experiments in our lab using electron microscopy showed that the murine PMN 
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have only approximately seven mitochondria per cell compared to other mammalian cells 
which can average between 100-1000 mitochondria per cell (data not shown; (Arthur 
Kornberg, 2005). Recent studies have demonstrated a metabolic role for mitochondria in 
PMN chemotaxis. They have shown that in response to FPR engagement, mitochondria 
generate the first burst of ATP that is released from the cell and that positive feedback 
through P2Y2 leads to increased mitochondrial activity near the leading edge of a polarized 
cell (Y. Bao et al., 2015; Y. Bao et al., 2014). The present study provides further evidence 
that beyond regulating apoptotic mechanisms, mitochondrial metabolism may play a 
significant role in PMN-MDSC-L function. 
In spite of increased metabolic rates, we were unable to confirm that the total pool 
of ATP was increased in PMN-MDSC-L. However, there are several limitations to these 
experiments. First, we currently do not know the rate at which ATP is released by 
pannexin-1 hemichannels. If the number of ATP molecules released is greater than the 
number produced, the intracellular pool of ATP would appear unchanged compared to 
levels in PMN. Second, while we inhibited ectonucleotidases to try to measure ATP levels 
in the supernatant of cultured cells, binding of ATP to purinergic receptors would prevent 
us from detecting the total pool of ATP that is released. Taken together, these caveats 
suggest that instead of using endpoint assays to capture a potential buildup of ATP, in order 
to capture this dynamic process, we must use a kinetic assay, discussed further in the next 
section. 
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Significance 
In this dissertation, we have shown that enhanced spontaneous migration is only 
observed in PMN-MDSC-L from transgenic models and mice in the early stages of tumor 
development, but not in transplantable models or mice in the late stages of tumor 
development, and that these results are linked to the metabolic profile and 
immunosuppressive capability of the cells. These observations raise the obvious next 
question: What is the role of these cells in cancer? 
In 1889, Steven Paget proposed the seed-and-soil hypothesis to explain how 
metastases develop. He proposed that factors secreted during primary tumor progression 
act systemically at distant secondary sites, modifying the local tissue environment (soil), 
and recruiting immune cells to further condition these sites for the successful colonization 
by tumor cells (seed) (Paget, 1989). In 2005, Rosandra Kaplan coined the term “pre-
metastatic niche” by showing that VEGFR1+ hematopoietic progenitor cells home to 
specific tissue sites prior to the arrival of tumor cells, and that metastasis development was 
dependent on these cells (Kaplan et al., 2005). Since this study, several papers have 
implicated immune cells in the development of the pre-metastatic niche and there are many 
studies suggesting a role for PMN-MDSC in this process (T. Condamine et al., 2015; Huh 
et al., 2010; Ichikawa et al., 2011; Kowanetz et al., 2010; Sceneay et al., 2012; Seubert et 
al., 2015; Q. Yang et al., 2017). It is important to note that these studies all provide evidence 
of chemoattractant-mediated recruitment of PMN-MDSC to these secondary organs, often 
the result of signaling induced by the primary tumor. We propose that the enhanced 
spontaneous migratory, possibly invasive, behavior of PMN-MDSC-L uniquely poises 
75 
 
these cells to aid in the development of the pre-metastatic niche, even in the absence of 
chemoattractant-mediated recruitment. Because these cells develop under relatively low 
inflammatory conditions, we predict that they will develop either in the very early stages 
of tumor development or in patients in remission where few tumor cells evade the effects 
of therapies. Therefore, they could contribute to the early dissemination and seeding of 
cancer cells in secondary organs, or facilitate disease recurrence. It is unclear if these cells 
persist during tumor progression when bona fide PMN-MDSC develop, but are present at 
such a small percentage of the population that they are overlooked, or if persistent 
inflammatory signaling forces these cells to develop into bona fide immunosuppressive 
PMN-MDSC. 
Finally, the field of MDSC research has taken off in the past 10 years, with over 
2500 articles published, lending significant insight into immunosuppressive mechanisms 
of MDSC in mice and humans (D. I. Gabrilovich, 2017). However, while we have been 
able to distinguish PMN from PMN-MDSC using density centrifugation and have recently 
identified LOX1 as a marker for PMN-MDSC in humans, we have not made any advances 
in separating murine PMN from PMN-MDSC (Thomas Condamine et al., 2016). 
Currently, we assume that all the CD11b+GR1+ cells in a tumor-bearing mouse are MDSC. 
Our studies have identified a potential novel stage in the development of PMN-MDSC, one 
that is characterized by metabolic changes, altered migratory behavior, and weak 
immunosuppressive ability. These findings may shift our understanding of the PMN-
MDSC population in mouse models. 
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Future Directions 
As is the case with any scientific endeavor, these studies have raised more questions 
than they have answered. We have demonstrated some fundamental differences between 
naïve PMN, PMN-MDSC-L, PMN-MDSC. To explore our mechanistic insights further, it 
would be interesting to conduct a screen of the purinergic receptors expressed on the cell 
surface of these cells, and observe whether their expression changes over the course of 
tumor progression. Additionally, because pharmacologic inhibitors of purinergic receptors 
can often target more than one receptor, we could utilize genetic mouse models such as 
P2X1 or pannexin-1 hemichannel knockout mice to confirm our mechanistic findings. 
These genetic models may also help uncover any redundant purinergic signaling pathways. 
Finally, RNA-seq analysis on these three cell types would allow us to explore the 
transcriptional changes that occur in these cells, lend further insight into the functional 
changes we have observed, and help us understand the stages of bona fide PMN-MDSC 
development.  
In this study, we have proposed that an alternative signaling pathway downstream 
of purinergic receptor signaling, one that is independent of RhoA activation, could lead to 
the phosphorylation of MLC2 and actomyosin contraction. In smooth muscle cells, 
engagement of purinergic receptors results in an influx of calcium and leads to MLCK-
mediated phosphorylation of MLC2 (Kwon, Jung, Cho, Jeong, & Sohn, 2015). Several 
studies have demonstrated that ROCK and MLCK can phosphorylate Ser19 on MLC2 in 
various cell types (Aguilar, Tracey, Tsang, McGinnis, & Mitchell, 2011; Amano et al., 
1996; Eikemo et al., 2016). In fact, both kinases have been shown to play a role in T-cell 
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migration  (A. Smith, Bracke, Leitinger, Porter, & Hogg, 2003). Moreover, MLCK 
inhibitors have been shown to impair uropod retraction (Eddy, Pierini, Matsumura, & 
Maxfield, 2000). However, to our knowledge, while the ability of ROCK to phosphorylate 
MLC2 has been shown, direct evidence of MLCK-mediated phosphorylation of MLC2 in 
neutrophils has never been demonstrated (Niggli, 1999). To test if purinergic receptor-
mediated calcium influx leads to the activation of MLCK and subsequent phosphorylation 
of MLC2, we could treat PMN-MDSC-L with the MLCK inhibitor ML-7 to see if this 
abolishes their ability to spontaneously migrate and confirm if this effect is mediated 
through phosphorylation of MLC2 by western blot.  
Next, because we have shown that Glut1 cell surface expression is increased on 
PMN-MDSC-L and that this contributes to the metabolic changes in PMN-MDSC-L, we 
would like to understand more about the regulation of Glut1. Because we did not observe 
any transcriptional changes in Glut1 expression, we assume that Glut1 cell surface 
expression is regulated by Glut1 translocation from the cytoplasm to the cell surface. We 
could investigate this possibility by separating the plasma membrane from intracellular 
membranes using centrifugation and probe for Glut1 by western blot. 
As discussed in the previous section, we could try an alternative approach to 
measure glucose uptake to confirm that Glut1-mediated increase of glucose uptake is what 
drives the increases in glycolytic rates that we have observed. To test this, we can culture 
cells in the presence of heavy-labeled 13C-glucose and use mass spectrometry to measure 
glucose uptake. This strategy would also give us further insight into the metabolic 
pathways that were used and metabolites that were generated in PMN compared to PMN-
MDSC-L. Additionally, to capture ATP released by the cells, we could utilize the new 
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fluorescent probe 2-2Zn(II) and microscopy. This probe has a polyethylene glycol linker 
that facilitates binding of 2-2Zn(II) to the cell surface of living cells, and would allow for 
real-time fluorescent visualization and quantitation of the amount of ATP that is released 
by PMN and PMN-MDSC-L (C. Ledderose, Bao, Zhang, & Junger, 2015).  
To address our hypothesis that PMN-MDSC-L play a role in the development of 
the pre-metastatic niche, we need to determine if these cells that are highly motile in two 
dimensions are capable of invading tissues. To test this hypothesis, we could utilize two 
approaches. First, we could utilize an in vitro approach and evaluate the ability of PMN 
and PMN-MDSC-L to migrate through Matrigel-coated transwells. Second, we could 
utilize an in vivo approach and evaluate the ability of PMN and PMN-MDSC-L to directly 
invade tissues. For example, for these experiments, we could intravenously inject a mix of 
CD45.1 PMN and CD45.2 PMN-MDSC-L into a double positive recipient and evaluate 
the ability of these cells to invade various tissues by flow cytometry. Alternatively, we 
could utilize whole body GFP and RFP mice for these purposes, or any strategy that would 
allow us to differentiate injected PMN and PMN-MDSC-L from the host’s PMN. As a next 
step, we would want to make the connection between extracellular ATP, purinergic 
receptor signaling and the development of metastases. We could treat a mouse model that 
is known to generate PMN-MDSC-L and develop metastases with apyrase, suramin, or 
NF449 and compare the development of metastases to untreated mice. We could then 
deplete Ly6G+ cells to demonstrate the effect on metastasis development is truly dependent 
upon PMN-MDSC-L and not upon other cells that also utilize extracellular ATP and 
purinergic receptor signaling.  
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Finally, we must consider the implications of these findings on patient care. PMN-
MDSC-L develop under low inflammatory conditions and can be distinguished from naïve 
PMN by their enhanced migratory behavior, increased Glut1 expression, and possibly by 
their purinergic receptor expression. If these findings are recapitulated in humans, 
screening for these cells and markers in the bone marrow biopsies of patients receiving 
treatment for leukemias using flow cytometry could serve as a surrogate or confirmatory 
marker of minimal residual disease, and guide treatment options.  
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